New treatments for triple negative breast cancer using modified taxane compounds
Official title: Novel taxane-site tubulin ligands with a dual apoptosis and senescence-inducing mechanism of action
Funded at Albert Einstein College of Medicine · NIH-11010876 · Data updated 2026-11-12
This study is exploring new treatments made from natural compounds that could help fight triple negative breast cancer by not only killing cancer cells but also stopping them from coming back, which could be great news for patients who haven't had success with other therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $481,953 |
| NIH project number | 5R01CA279952-02 |
| Project ID | NIH-11010876 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple negative breast cancer, particularly those who have not responded to standard treatments.
✕Less likely to help
Patients with non-breast cancers or those whose breast cancer is not triple negative may not benefit from this research.
What this research studies
This research investigates innovative compounds derived from taxanes that can induce both cell death and a state of senescence in triple negative breast cancer cells. By targeting the mechanisms of apoptosis and senescence, the study aims to create therapies that are more effective against cancer cells that have become resistant to existing treatments. The researchers will utilize advanced techniques like X-ray crystallography to refine these compounds and assess their effectiveness in preclinical models. Patients may benefit from therapies that not only kill cancer cells but also prevent their regrowth.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with triple negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Other research has shown promise in using similar approaches to target cancer cells, indicating potential for success in this novel treatment strategy.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Mcdaid, Hayley M. — Albert Einstein College of Medicine
- Study coordinator: Mcdaid, Hayley M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.